VRTX - Vertex Pharmaceuticals Incorporated
ABN Amro Investment Solutions boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 257.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,216 shares of the pharmaceutical company's stock after buying an additional 49,146 shares during the quarter.
Andra AP fonden cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 33.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,903 shares of the pharmaceutical company's stock after selling 12,037 shares during the quarter. Andra
Amova Asset Management Americas Inc. lowered its stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 66.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,115 shares of the pharmaceutical company's stock after selling 4,199 shares during the period. Amova
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.
Boston Common Asset Management LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 7.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,205 shares of the pharmaceutical company's stock after purchasing an additional 1,124 shares
Broderick Brian C grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 8.5% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 18,656 shares of the pharmaceutical company's stock after buying an additional 1,454 shares during the period. Vertex Pharmaceuticals makes up about 1.5% of
Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential. The company's business is strong thanks to its dominance in its core market and new launches in other areas.
Assetmark Inc. lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 33.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,954 shares of the pharmaceutical company's stock after selling 30,529 shares during the quarter. Assetmark Inc.'s holdings in Vertex
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.
Vertex Pharmaceuticals is making clinical and regulatory progress with some promising candidates. The company's most important business is still performing well.
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has taken key steps in recent years to expand into other treatment areas, and efforts have been bearing fruit.
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, named Roundhill Memory ETF (NASDAQ:DRAM) as her final trade.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideratio.
Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceuticals NASDAQ: CRNX for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.